Venetoclax Powder CAS 1257044-40-8 Abt-199 Venetoclax

• Customization: Available
• Powder: Yes
• Customized: Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >98%
• Sample: Available
• OEM: Available
• MOQ: 1kg
• Keyword 1: Venetoclax
• Keyword 2: Venetoclax Powder
• Storage: Dry and Cool Place
• Transport Package: Foil Bag/25kg Drum
• Specification: 98%
• Trademark: /
• Origin: China
• Production Capacity: 10000

Product Description

Description
ABT-199 is a yellow powder, Venetoclax, also known as ABT-199 or GDC0199, ABT-199 is an orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. ABT-199 mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cell

Name	ABT-199
Grade	Pharmaceutical Grade
Appearance	yellow powder
Specification	98%

Function
ABT-199 is a small molecule oral drug that treats chronic lymphocytic leukemia (CLL) in those with a specific chromosomal abnormality.In 2015, the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to venetoclax for subjects with CLL who have relapsed or have been refractory to previous treatment and have the 17p deletion genetic mutation.
Application
ABT-199 is a yellow powder, Venetoclax, also known as ABT-199 or GDC0199, ABT-199 is an orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. ABT-199 mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells